Chemokines as molecular targets for therapeutic intervention

Journal of Clinical Immunology

Volumn 19, Issue 5, 1999, Pages 280-292

  Zack Howard, O M ^a   Oppenheim, Joost J ^a   Wang, Ji Ming ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Antagonists; Chemokine receptors; Chemokines

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 2,2' [4,4' [(AMINOCARBONYL)AMINO]BIS[N 4' DI(PYRROLE 2 CARBOXAMIDE 1,1' DIMETHYL)] 6,8 NAPHTHALENEDISULFONIC ACID]HEXASODIUM; 4 HYDROXYPIPERIDINE DERIVATIVE; BICYCLAM; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GUANINE NUCLEOTIDE BINDING PROTEIN; HAMYCIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 8; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEUTRALIZING ANTIBODY; PEPTIDE DERIVATIVE; RANTES; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CHEMOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEPTIDES; RECEPTORS, CHEMOKINE;

EID: 0032884283     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020587407535     Document Type: Review

References (98)

1. 1. Baggiolini M: Chemokines and leukocyte traffic. Nature 392:565-568, 1998
2. 2. Zlotnik A, Morales J, Hedrick JA: Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 19:1-47, 1999
3. 3. Rollins BJ: Chemokines. Blood 90:909-928, 1997
4. 4. Howard OM, Ben-Baruch A, Oppenheim JJ: Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol 14:46-51, 1996
5. 5. Yang D, Chertov O, Bykovskaia S, et al.: Human beta-defensins promote adaptive immunity, by activating dendritic and T cells expressing CCR6. Science (in press)
6. 6. Oppenheim JJ, Wang JM, Chertov O, et al.: The role of chemokines in transplantation. In Transplant Biology, NL Tilney, TB Storm, LC Paul (eds). Philadelphia, Lippincott-Raven, 1996, pp 187-220
7. 7. Littman DR: Chemokine receptors: Keys to AIDS pathogenesis? Cell 93:677-680, 1998
8. Kledal TN, Rosenkilde MM, Coulin F, et al.: A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277:1656-1659, 1997
9. 9. Lalani AS, McFadden G: Secreted poxvirus chemokine binding proteins. J Leukocyte Biol 62:570-566, 1997
10. 10. Yang X-D, Corvalan JRS, Wang T, et al.: Fully human anti IL-8 monoclonal antibody: Potential therapeutics for the treatment of inflammatory disease states. J Leukocyte Biol 66:401-410, 1999
11. 11. Harada A, Sekido N, Akahoshi T, et al.: Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukocyte Biol 56:559-564, 1994
12. 12. Matsumoto T, Yokoi K, Mukaida N, et al.: Pivotal role of interleukin-8 in the acute respiratory distress syndrome and cerebral reperfusion injury. J Leukocyte Biol 62:581-587, 1997
13. 13. Ono K, Matsumori A, Furukawa Y, et al.: Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 79:195-203, 1999
14. 14. Lloyd C, Gutierrez-Ramos JC: The role of chemokines in tissue inflammation and autoimmunity in renal diseases. Curr Opin Nephrol Hypertens 7:281-287, 1998
15. 15. Arenberg DA, Kunkel SL, Polverini PJ, et al.: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97:2792-2802, 1996
16. 16. Karpus WJ, Kennedy KJ: MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 62: 681-768, 1997
17. 17. Greenberger MJ, Strieter RM, Kunkel SL, et al.: Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 173:159-165, 1996
18. 18. Moser B, Dewald B, Barella L, et al.: Interleukin-8 antagonists generated by N-terminal modification. J Biol Chem 268:7125 7158, 1993
19. 19. Baly DL, Horuk R, Yansura DG, et al.: A His 19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor. J Immunol 161:4944-4949, 1998
20. 20. Hayashi SJ, Kurdowska A, Miller EJ, et al.: Synthetic hexa-and heptapeptides that inhibit IL-8 from binding to and activating human blood neutrophils. J Immunol 154:814-824, 1995
21. 21. Miller EJ, Cohen AB, Peterson BT: Peptide inhibitor of interleukin-8 (IL-8) reduces staphylococcal enterotoxin-A (SEA) induced neutrophil trafficking to the lung. Inflamm Res 45:393-397, 1996
22. 22. Hayashi S, Kurdowska A, Cohen AB, et al.: A synthetic peptide inhibitor for alpha-chemokines inhibits the growth of melanoma cell lines. J Clin Invest 99:2581-2587, 1997
23. 23. Fujisawa N, Hayashi S, Miller EJ: A synthetic peptide inhibitor for alpha-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice [in process citation]. Melanoma Res 9:105-114, 1999
24. 24. Fujisawa N, Hayashi S, Kurdowska A, et al.: Inhibition of GROalpha-induced human endothelial cell proliferation by the alpha-chemokine inhibitor antileukinate. Cytokine 11:231-238, 1999
25. 25. Zhang YJ, Rutledge BJ, Rollins BJ: Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 269:15918-15924, 1994
26. 26. Gong JH, Clark-Lewis I: Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 181:631-640, 1995
27. 27. Gong JH, Ratkay LG, Waterfield JD, et al.: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model. J Exp Med 186:131-137, 1997
28. 28. Gong JH, Uguccioni M, Dewald B, et al.: RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 271:10521-10527, 1996
29. 29. Murakami T, Nakajima T, Koyanagi Y, et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389-1393, 1997
30. 30. Tamamura H, Imai M, Ishihara T, et al.: Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem 6:1033-1041, 1998
31. 31. Crump MP, Gong JH, Loetscher P, et al.: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16:6996-7007, 1997
32. 32. Loetscher P, Gong JH, Dewald B, et al.: N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J Biol Chem 273:22279-22283, 1998
33. 33. Heveker N, Montes M, Germeroth L, et al.: Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr Biol 8:369-376, 1998
34. 34. Mack M, Luckow B, Nelson PJ, et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J Exp Med 187:1215-1224, 1998
35. 35. Simmons G, Clapham PR, Picard L, et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279, 1997
36. 36. Proudfoot AE, Power CA, Hoogewerf AJ, et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271:2599-2603, 1996
37. 37. Elsner J, Petering H, Kimmig D, et al.: The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int Arch Allergy Immunol 118:462-465, 1999
38. 38. Yang OO, Swanberg SL, Lu Z, et al.: Enhanced inhibition of human immunodeficiency virus type I by Met-stromal-derived factor 1beta correlates with down-modulation of CXCR4. J Virol 73:4582-4589, 1999
39. 39. Chen JD, Bai X, Yang AG, et al.: Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med 3:1110-1116, 1997
40. 40. Yang AG, Bai X, Huang XF, et al.: Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Natl Acad Sci USA 94:11567-11572, 1997
41. 41. White JR, Lee JM, Young PR, et al.: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095-10098, 1998
42. 42. De Clercq E, Yamamoto N, Pauwels R, et al.: Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 89:5286-5290, 1992
43. 43. Donzella GA, Schols D, Lin SW, et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77, 1998
44. 44. Schols D, Struyf S, Van Damme J, et al.: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388, 1997
45. 45. Labrosse B, Brelot A, Heveker N, et al.: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381-6388, 1998
46. 46. de Vreese K, Kofler-Mongold V, Leutgeb C, et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 70:689-696, 1996
47. 47. Schols D, Este JA, Cabrera C, et al.: T-cell-line-tropic human immunodeficiency virus type I that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 72:4032-4037, 1998
48. 48. Este JA, Cabrera C, Blanco J, et al.: Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4 [in process citation]. J Virol 73:5577-5585, 1999
49. 49. Ma Q, Jones D, Borghesani PR, et al: Impaired B-lymphopoiesis, myclopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA 95:9448-9453, 1998
50. 50. Nagasawa T, Hirota S, Tachibana K, et al: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:635-638, 1996
51. 51. Salcedo R, Wasserman K, Young HA, et al.: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125-1135, 1999
52. 52. Hesselgesser J, Ng HP, Liang M, et al: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273:15687-15692, 1998
53. 53. Cooke SP, Forrest G, Venables PJ, et al: The delta32 deletion of CCR5 receptor in rheumatoid arthritis. Arth Rheum 41:1135-1136, 1998
54. 54. Altman GB, Altman LC, Luchtet DL, et al: Release of RANTES from nasal and bronchial epithelial cells. Cell Biol Toxicol 13:205-213, 1997
55. 55. Garred P, Madsen HO, Petersen J, et al.: CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 25:1462-1465, 1998
56. 56. Karpus WJ, Lukacs NW, McRae BL, et al.: An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 155:5003-5010, 1995
57. 57. Serody JS, Cook DN, Kirby SL, et al.: Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 93:43-50, 1999
58. 58. Baba M, Nishimura O, Kanzaki N, et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96:5698-5703, 1999
59. 59. Whitby D, Boshoff C: Kaposi's sarcoma herpesvirus as a new paradigm for virus-induced oncogenesis. Curr Opin Oncol 10:405 412, 1998
60. 60. Verma MJ, Lloyd A, Rager H, et al.: Chemokines in acute anterior uveitis. Curr Eye Res 16:1202-1208, 1997
61. 61. Terada N, Maesako K, Hamano N, et al.: RANTES production in nasal epithelial cells and endothelial cells. J Allergy Clin Immunol 98:S230-237, 1996
62. 62. Ciomei M, Pastori W, Mariani M, et al: New sulfonated distamycin A derivatives with hFGF complexing activity, Biochem Pharmacol 47:205-302, 1994
63. 63. Sola F, Farao M, Ciomei M, et al: FCE, 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis 15:222-231, 1995
64. 64. Sola F, Farao M, Pesenti E, et al.: Antitumor activity of FCE 26644 a new growth-factor complexing molecule. Cancer Chemother Pharmacol 36:217-222, 1995
65. 65. Clanton DJ, Buckheit RW Jr, Terpening SJ, et al.: Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res 27:335-354, 1995
66. 66. Howard OM, Oppenheim JJ, Hollingshead MG, et al: Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: A candidate for chemotherapeutic and microbicidal application. J Med Chem 41:2184-2193, 1998
67. 67. Howard OM, Korte T, Tarasova NI, et al.: Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 64:6-13, 1998
68. 68. Mosier DE, Picchio GR, Gulizia RJ, et al: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 73:3544-3550, 1999
69. 69. Howard OM, Shirakawa AK, Turpin JA, et al.: Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function. J Biol Chem 274:16228-16234, 1999
70. 70. Manna SK, Samanta S, Samanta AK: Hamycin inhibits IL-8-induced biologic response by modulating its receptor in human polymorphonuclear neutrophils. J Immunol 159:5042-5052, 1997
71. 71. Thomas AH: Analysis and assay of polyene antifungal antibiotics. A review. Analyst 101:321-340, 1976
72. 72. Thomas AH: Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 17:269-279, 1986
73. 73. Moonis M, Ahmad I, Bachhawat BK: Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. J Antimicrob Chemother 31:569 579, 1993
74. 74. Mehta RT, McQueen TJ, Keyhani A, et al.: Liposomal hamycin: Reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis 164:1003-1006, 1991
75. 75. Sozzani S, Bonecchi R, D'Amico G, et al.: Old and new chemokines. Pharmacological regulation of chemokine production and receptor expression: Mini-review. J Chemother 10:142-145, 1998
76. 76. Rovai LE, Herschman HR, Smith JB: The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukocyte Biol 64:494-502, 1998
77. 77. Standiford TJ, Kunkel SL, Rolfe MW, et al.: Regulation of human alveolar macrophage-and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol 6:75-81, 1992
78. 78. Kovacs EJ, Faunce DE, Ramer-Quinn DS, et al.: Estrogen regulation of JE/MCP-1 mRNA expression in fibroblasts. J Leukocyte Biol 59:562-568, 1996
79. 79. Slavin J, Unemori E, Hunt TK, et al.: Monocyte chemotactic protein-1 (MCP-1) mRNA is down-regulated in human dermal fibroblasts by dexamethasone: Differential regulation hy TGF-beta. Growth Factors 12:151-157, 1995
80. 80. Yamada K, Hayashi T, Kuzuya M, et al.: Physiological concentration of 17 beta-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. Artery 22:24-35, 1996
81. 81. Wang P, Wu P, Anthes JC, et al.: Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 83:2678-2683, 1994
82. 82. Tumpey TM, Cheng H, Yan XT, et al.: Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10, J Leukocyte Biol 63:486-492, 1998
83. 83. Gerritsma JS, van Kooten C, Gerritsen AF, et al.: Transforming growth factor-beta 1 regulates chemokine and complement production by human proximal tubular epithelial cells. Kidney Int 53:609-616, 1998
84. 84. Kucharzik T, Lugering N, Pauels HG, et al.: IL-4, IL-10 and IL-13 down-regulate monocyte-chemoattracting protein-1 (MCP-1) production in activated intestinal epithelial cells. Clin Exp Immunol 111:152-157, 1998
85. 85. John M, Au BT, Jose PJ, et al.: Expression and release of interleukin-8 by human airway smooth muscle cells: Inhibition by Th-2 cytokines and corticosteroids. Am J Respir Cell Mol Biol 18:84-90, 1998
86. 86. Hedrick JA, Helms A, Vicari A, et al.: Characterization of a novel CC chemokine, HCC-4, whose expression is increased by interleukin-10. Blood 91:4242-4247, 1998
87. 87. Ohmori Y, Hamilton TA: The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol 154:5235-5244, 1995
88. 88. Whitson RH Jr, Wong WL, Itakura K: Platelet factor 4 selectively inhibits binding of TGF-beta 1 to the type I TGF-bela 1 receptor, J Cell Biochem 47:31-42, 1991
89. 89. Szabo C, Scott GS, Virag L, et al.: Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 125:379-387, 1998
90. 90. Verghese MW, Kneisler TB, Boucheron JA: P2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells. J Biol Chem 271:15597-15601, 1996
91. 91. Grimm MC, Ben-Baruch A, Taub DD, et al.: Opiates transdeactivate chemokine receptors: Delta and mu opiate receptor-mediated helerologous desensitization. J Exp Med 188:317-325, 1998
92. 92. Ali H, Richardson RM, Haribabu B, et al.: Chemoattractant receptor cross-desensitization. J Biol Chem 274:6027-6030, 1999
93. 93. Au BT, Teixeira MM, Collins PD, et al.: Effect of PDE4 inhibitors on zymosan-induced IL 8 release from human neutrophils; Synergism with prostanoids and salbutamol. Br J Pharmacol 123:1260 1266, 1998
94. 94. Su SB, Gao J, Gong W, et al.: T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes hy using G-protein-coupled formyl peptide receptors. J Immunol 162:5924-5930, 1999
95. 95. Su SB, Gong WH, Gao JL, et al.: T20/DP178, an ectodomian peptide of human immunodeficiency virus type I gp41. is an activator of human phagocyte N-formyl peptide receptor. Blood 93:3885-3892, 1999
96. 96. Deng X, Ueda H, Su SB, et al.: A synthetic peptide derived from HIV-1 gp120 down-regulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the seven-transmembrane G protein-coupled receptor FPRL-I/ LXAR, Blood 94:1165-1173, 1999
97. 97. Su SB, Gong W, Gao JL, et al.: A seven-transmembrane, G protein-coupled receptor, FPRLI, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189:395-402, 1999
98. 98. Badolato R, Johnston JA, Wang JM, et al.: Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol 155:4004-4010, 1995